Angiotensin-converting enzyme inhibition in myocardial infarction--Part 2: Clinical issues and controversies.
Victor F. Huckell(University of British Columbia Hospital), Andreas Wielgosz(University of Ottawa), S. Isserow, Pierre Laramée, J. Wayne Warnica, Victoria Bernstein, Brandi Quinn, P. Liu(Prince of Wales Hospital), Fabio Maria Turazza, Rebecca Crowell, Robert C. Orchard(Southwestern Medical Center), Gilles R. Dagenais(Institut universitaire de cardiologie et de pneumologie de Québec), Lyall Higginson(University of Ottawa), M Samson, Richard M. Prewitt, John McCans
PubMed
February 1, 1997
Cited by 3
Related Papers
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
|The Lancet|2019|3.1k
World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions
|The Lancet Global Health|2019|1.2k
Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study
|The Lancet|2017|1.1k
Cardiovascular Risk and Events in 17 Low-, Middle-, and High-Income Countries
|New England Journal of Medicine|2014|993